阳光诺和：STC008注射液的核心适应症为肿瘤恶液质

Core Viewpoint - The core indication of STC008 injection is cancer cachexia, which encompasses cachexia states caused by various cancer types, not limited to non-small cell lung cancer [2] Group 1 - The company stated that the previously disclosed domestic BD agreement for STC008 mentioned "cachexia in non-small cell lung cancer" based on the focus of clinical research during the collaboration phase [2] - Currently, STC008 is undergoing Phase I clinical trials aimed at exploring its safety and preliminary efficacy in patients with cachexia, without restricting to specific cancer types [2] - The company plans to cautiously evaluate the feasibility of expanding to cachexia caused by multiple cancer types based on existing clinical research data, clinical needs, research progress, and regulatory requirements [2]